000079125 001__ 79125
000079125 005__ 20200113145619.0
000079125 0247_ $$2doi$$a10.1007/s10096-017-3129-y
000079125 0248_ $$2sideral$$a106556
000079125 037__ $$aART-2018-106556
000079125 041__ $$aeng
000079125 100__ $$aLorente, L.
000079125 245__ $$aSustained high serum caspase-3 concentrations and mortality in septic patients
000079125 260__ $$c2018
000079125 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079125 5203_ $$aCaspase-3 is the main executor of the apoptotic process. Higher serum caspase-3 concentrations in non-survivor compared to survivor septic patients have been found. The objectives of this work (with the increase of sample size to 308 patients, and the determination of serum caspase-3 concentrations also on days 4 and 8 of diagnosis of severe sepsis) were to know whether an association between serum caspase-3 concentrationss during the first week, degree of apoptosis, sepsis severity, and sepsis mortality exists. We collected serum samples of 308 patients with severe sepsis from eight intensive care units on days 1, 4 and 8 to measure concentrations of caspase-3 and caspase-cleaved cytokeratin (CCCK)-18 (to assess degree of apoptosis). End point was 30-day mortality. We found higher serum concentrations of caspase-3 and CCCK-18 in non-survivors compared to survivors on days 1 (p < 0.001), 4 (p < 0.001), and 8 (p < 0.001). We found an association between serum caspase-3 concentrations on days 1, 4 and 8 of severe sepsis diagnosis and serum CCCK-18 concentrations (p < 0.001), SOFA (p < 0.001), serum acid lactic concentrations (p < 0.001), and 30-day sepsis mortality (p < 0.001). The new findings of this work were that an association between serum caspase-3 concentrations during the first week, apoptosis degree, sepsis severity, and sepsis mortality exists.
000079125 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/INT16-00165$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI14-00220
000079125 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000079125 590__ $$a2.591$$b2018
000079125 591__ $$aMICROBIOLOGY$$b78 / 133 = 0.586$$c2018$$dQ3$$eT2
000079125 591__ $$aINFECTIOUS DISEASES$$b46 / 89 = 0.517$$c2018$$dQ3$$eT2
000079125 592__ $$a1.208$$b2018
000079125 593__ $$aInfectious Diseases$$c2018$$dQ1
000079125 593__ $$aMicrobiology (medical)$$c2018$$dQ1
000079125 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000079125 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000079125 700__ $$aMartín, M.M.
000079125 700__ $$aPérez-Cejas, A.
000079125 700__ $$aGonzález-Rivero, A.F.
000079125 700__ $$aLópez, R.O.
000079125 700__ $$aFerreres, J.
000079125 700__ $$aSolé-Violán, J.
000079125 700__ $$0(orcid)0000-0002-3312-9383$$aLabarta, L.$$uUniversidad de Zaragoza
000079125 700__ $$aDíaz, C.
000079125 700__ $$aPalmero, S.
000079125 700__ $$aJiménez, A.
000079125 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000079125 773__ $$g37, 2 (2018), 281-288$$pEur. j. clin. microbiol. infect. dis.$$tEUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES$$x0934-9723
000079125 8564_ $$s758298$$uhttps://zaguan.unizar.es/record/79125/files/texto_completo.pdf$$yPostprint
000079125 8564_ $$s73453$$uhttps://zaguan.unizar.es/record/79125/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000079125 909CO $$ooai:zaguan.unizar.es:79125$$particulos$$pdriver
000079125 951__ $$a2020-01-13-14:54:52
000079125 980__ $$aARTICLE